PL2954049T3 - Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu - Google Patents

Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu

Info

Publication number
PL2954049T3
PL2954049T3 PL14706207.9T PL14706207T PL2954049T3 PL 2954049 T3 PL2954049 T3 PL 2954049T3 PL 14706207 T PL14706207 T PL 14706207T PL 2954049 T3 PL2954049 T3 PL 2954049T3
Authority
PL
Poland
Prior art keywords
attenuation
respiratory syncytial
syncytial virus
human respiratory
genome scale
Prior art date
Application number
PL14706207.9T
Other languages
English (en)
Inventor
Steffen Mueller
Eckard Wimmer
Peter L. Collins
Cyril LE NOUËN
Linda G. Brock
Ursula J. Buchholz
Joshua Marc Dinapoli
Original Assignee
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Steffen Mueller
Eckard Wimmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Steffen Mueller, Eckard Wimmer filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Publication of PL2954049T3 publication Critical patent/PL2954049T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00061—Methods of inactivation or attenuation
    • C12N2760/00062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14706207.9T 2013-02-08 2014-02-07 Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu PL2954049T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762768P 2013-02-08 2013-02-08
US201361794155P 2013-03-15 2013-03-15
PCT/US2014/015274 WO2014124238A1 (en) 2013-02-08 2014-02-07 Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Publications (1)

Publication Number Publication Date
PL2954049T3 true PL2954049T3 (pl) 2023-10-16

Family

ID=50156946

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14706207.9T PL2954049T3 (pl) 2013-02-08 2014-02-07 Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu

Country Status (8)

Country Link
US (4) US9957486B2 (pl)
EP (2) EP4190895A1 (pl)
AU (4) AU2014214763B2 (pl)
CA (1) CA2900713A1 (pl)
ES (1) ES2952387T3 (pl)
HR (1) HRP20230694T1 (pl)
PL (1) PL2954049T3 (pl)
WO (1) WO2014124238A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2954049T3 (pl) * 2013-02-08 2023-10-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu
AU2014239583B2 (en) 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
HRP20200012T1 (hr) 2013-03-15 2020-03-20 The Research Foundation Of The State University Of New York Atenuirani virusi i cjepiva gripe
US10342861B2 (en) 2014-05-27 2019-07-09 University Of Rochester Arenavirus vaccine
JP7311872B2 (ja) 2015-10-29 2023-07-20 エモリー ユニバーシティー キメラｒｓｖ、免疫原性組成物、及び使用方法
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
BR112020012241A2 (pt) 2017-12-22 2020-11-24 Codagenix Inc. vírus recombinante com a região não otimizada com codon-par e usos para o tratamento do câncer
US12168049B2 (en) 2018-03-08 2024-12-17 Codagenix Inc. Attenuated flaviviruses
AU2021271702A1 (en) * 2020-05-13 2023-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RSV vaccine bearing one or more P gene mutations
WO2021248086A2 (en) * 2020-06-05 2021-12-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated respiratory syncytial virus
WO2025128971A1 (en) * 2023-12-14 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345643T3 (es) 1996-07-15 2010-09-28 The Government Of The Usa, As Represented By The Department Of Health And Human Services Produccion de vacunas a base de virus respiratorio sincitial atenuado, a partir de secuencias nucleotidicas clonadas.
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
IL145796A0 (en) * 1999-04-13 2002-07-25 Us Health Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
AU2002223275A1 (en) * 2000-11-22 2002-06-03 Biota Scientific Management Pty Ltd A method of expression and agents identified thereby
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
EP1797173B1 (en) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation of replicative fitness by using less frequently used synonymous codons
WO2008121992A2 (en) * 2007-03-30 2008-10-09 Research Foundation Of State University Of New York Attenuated viruses useful for vaccines
KR20110063863A (ko) 2008-11-05 2011-06-14 머크 샤프 앤드 돔 코포레이션 생 약독화 호흡기 세포융합 바이러스
US10227569B2 (en) * 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
PL2954049T3 (pl) * 2013-02-08 2023-10-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Also Published As

Publication number Publication date
WO2014124238A1 (en) 2014-08-14
AU2014214763A1 (en) 2015-08-27
EP2954049B1 (en) 2023-05-17
ES2952387T3 (es) 2023-10-31
US20240417699A1 (en) 2024-12-19
EP4190895A1 (en) 2023-06-07
AU2022279509A1 (en) 2023-02-02
AU2020203460A1 (en) 2020-06-18
US11371024B2 (en) 2022-06-28
WO2014124238A8 (en) 2015-09-24
US9957486B2 (en) 2018-05-01
CA2900713A1 (en) 2014-08-14
HRP20230694T1 (hr) 2023-10-13
US12054749B2 (en) 2024-08-06
US20220325252A1 (en) 2022-10-13
AU2025237901A1 (en) 2025-10-16
EP2954049A1 (en) 2015-12-16
US20180208906A1 (en) 2018-07-26
AU2020203460B2 (en) 2022-09-08
AU2022279509B2 (en) 2025-06-26
AU2014214763B2 (en) 2020-02-27
US20150368622A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
PL2954049T3 (pl) Atenuacja ludzkiego syncytialnego wirusa oddechowego przez deoptymalizację par kodonów w skali genomu
IL258831A (en) Assemble respiratory syncytial virus
GB2521644B (en) Improvements relating to respiratory masks
SG10201801431TA (en) Respiratory syncytial virus (rsv) vaccine
SG11201601657WA (en) Devices to treat nasal airways
IL240504A0 (en) Combined vaccine for respiratory syncytial virus and influenza
GB201305171D0 (en) Measurement of tissue structures
GB2506621B (en) Respiratory mask
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
SMT202000145T1 (it) Epitopi di proteina f di virus sinciziale respiratorio
IL269622A (en) Preparation of (S–S)-scoisolaricirsinol diglucoside and (R–R)-scoisolaricisrinol diglucoside
SG11201505744XA (en) Human adaptation of h5 influenza
IL239309A0 (en) Methods for the treatment and prevention of respiratory conditions
SG11201510266SA (en) Dengue virus vaccine compositions and methods of use thereof
PL2874656T3 (pl) Atenuowane szczepionki przeciw grypie świń oraz ich sposoby wytwarzania i zastosowanie
PT2846806T (pt) Tratamento para depressão respiratória
EP2968394A4 (en) NEW VACCINES AGAINST MULTIPLE SUBTYPES OF THE DENGUE VIRUS
GB201215184D0 (en) Therapeutic virus
EP3353193A4 (en) CLEANING OF THE RESPIRATORY SYNZYTIAL VIRUS
AP2015008881A0 (en) Vaccines for diseases caused by viruses of the family of reoviridae
DK3228631T3 (da) Behandling af respiratoriske tilstande
EP2826486A4 (en) PRODUCT FOR TREATING VIRAL HEPATITIS C
PL3071575T3 (pl) Wytwarzanie normorfinanów
GB201320653D0 (en) Treatment of plants
UA24597S (uk) Респіраторна маска